Logo Logo
Hilfe
Hilfe
Switch Language to English

Duffy, M. J.; Harbeck, N.; Nap, M.; Molina, R.; Nicolini, A.; Senkus, E. und Cardoso, F. (2017): Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM). In: European Journal of Cancer, Bd. 75: S. 284-298

Volltext auf 'Open Access LMU' nicht verfügbar.

Abstract

Biomarkers play an essential role in the management of patients with invasive breast cancer. For selecting patients likely to respond to endocrine therapy, both oestrogen receptors (ERs) and progesterone receptors (PRs) should be measured on all newly diagnosed invasive breast cancers. On the other hand, for selecting likely response to all forms of antiHER2 therapy (trastuzumab, pertuzumab, lapatinib or ado-trastuzumab emtansine), determination of HER2 expression or gene copy number is mandatory. Where feasible, measurement of ER, PR and HER2 should be performed on recurrent lesions and the primary invasive tumour. Although methodological problems exist in the determination of Ki67, because of its clearly established clinical value, wide availability and low costs relative to the available multianalyte signatures, Ki67 may be used for determining prognosis, especially if values are low or high. In oestrogen receptor (ER)-positive, HER2-negative, lymph node negative patients, multianalyte tests such as urokinase plasminogen activator (uPA)-PAI-1, Oncotype DX, MammaPrint, EndoPredict, Breast Cancer Index (BCI) and Prosigna (PAM50) may be used to predict outcome and aid adjunct therapy decision-making. Oncotype DX, Mamma Print, EndoPredict and Prosigna may be similarly used in patients with 1-3 metastatic lymph nodes. All laboratories measuring biomarkers for patient management should use analytically and clinically validated assays, participate in external quality assurance programs, have established assay acceptance and rejection criteria, perfaun regular audits and be accredited by an appropriate organisation. (C) 2017 The Authors. Published by Elsevier Ltd.

Dokument bearbeiten Dokument bearbeiten